Tìm theo
Haloperidol
Các tên gọi khác (8 ) :
  • 1-(3-P-Fluorobenzoylpropyl)-4-P-chlorophenyl-4-hydroxypiperidine
  • 4-(4-(Para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
  • 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
  • 4'-Fluoro-4-(4-(P-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
  • 4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
  • gamma-(4-(P-Chlorophenyl)-4-hydroxpiperidino)-P-fluorbutyrophenone
  • Haldol
  • Haloperidolum
Thuốc điều trị về tâm thần
Thuốc Gốc
Small Molecule
CAS: 52-86-8
ATC: N05AD01
ĐG : Advanced Pharmaceutical Services Inc.
CTHH: C21H23ClFNO2
PTK: 375.864
A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279)
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C21H23ClFNO2
Phân tử khối
375.864
Monoisotopic mass
375.140134897
InChI
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
InChI Key
InChIKey=LNEPOXFFQSENCJ-UHFFFAOYSA-N
IUPAC Name
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
Traditional IUPAC Name
haloperidol
SMILES
OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
Độ tan chảy
151.5 °C
Độ hòa tan
14 mg/L (at 25 °C)
logP
4.30
logS
-4.43
pKa (strongest acidic)
13.96
pKa (Strongest Basic)
8.05
PSA
40.54 Å2
Refractivity
102.59 m3·mol-1
Polarizability
39.15 Å3
Rotatable Bond Count
6
H Bond Acceptor Count
3
H Bond Donor Count
1
Physiological Charge
1
Number of Rings
3
Bioavailability
1
Rule of Five
true
Ghose Filter
true
MDDR-Like Rule
true
pKa
8.66
Dược Lực Học : Haloperidol is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.
Cơ Chế Tác Dụng : A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279) The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ.
Dược Động Học :
▧ Absorption :
Oral-60%
▧ Protein binding :
92%
▧ Metabolism :
Hepatic
▧ Half Life :
3 weeks
Độc Tính : LD50=165 mg/kg (rats, oral)
Chỉ Định : For the management of psychotic disorders (eg. schizophrenia) and delirium, as well as to control tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome). Also used for the treatment of severe behavioural problems in children with disrubtive behaviour disorder or ADHD (attention-deficit hyperactivity disorder). Haloperidol has been used in the prevention and control of severe nausea and vomiting.
Tương Tác Thuốc :
  • Anisotropine Methylbromide The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Artemether Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
  • Atropine The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Benzatropine The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Biperiden The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Carbamazepine Carbamazepine may decrease the serum concentration of haloperidol by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of haloperidol if carbamazepine is initiated, discontinued or dose changed.
  • Clidinium The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Clozapine Clozapine, a moderate CYP2D6 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive CNS despresant and anticholinergic effects may also occur. Monitor for changes in the therapeutic and adverse effects of haloperidol if clozapine is initiated, discontinued or dose changed. Also monitor for increased CNS depressant and anticholinergic effects during concomitant therapy.
  • Dicyclomine The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Ethopropazine The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Fluconazole Fluconazole may increase the effect and toxicity of haloperidol.
  • Glycerol Phenylbutyrate Haloperidol may induce hyperammonemia. Monitor ammonia levels closely when use of haloperidol is necessary in UCD patients.
  • Glycopyrrolate The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Guanethidine Haloperidol may decrease the effect of guanethidine.
  • Homatropine Methylbromide The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Hyoscyamine The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Indacaterol Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system.
  • Isopropamide The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Itraconazole Itraconazole may increase the effect and toxicity of haloperidol.
  • Ketoconazole Ketoconazole may increase the effect and toxicity of haloperidol.
  • Lithium Possible extrapyramidal effects and neurotoxicity with this combination
  • Lumefantrine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Mepenzolate The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Mesoridazine Increased risk of cardiotoxicity and arrhythmias
  • Methantheline The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Methyldopa Methyldopa increases haloperidol effect or risk of psychosis
  • Orphenadrine The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Oxyphencyclimine The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Procyclidine The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Propantheline The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Propranolol Increased effect of both drugs
  • Rifabutin The rifamycin decreases the effect of haloperidol
  • Rifampicin The rifamycin decreases the effect of haloperidol
  • Scopolamine The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Tacrine The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Haloperidol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
  • Tacrolimus Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
  • Tamoxifen Haloperidol may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
  • Tamsulosin Haloperidol, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Haloperidol is initiated, discontinued, or dose changed.
  • Telithromycin Telithromycin may reduce clearance of Haloperidol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Haloperidol if Telithromycin is initiated, discontinued or dose changed.
  • Terbinafine Terbinafine may reduce the metabolism and clearance of Haloperidol. Consider alternate therapy or monitor for therapeutic/adverse effects of Haloperidol if Terbinafine is initiated, discontinued or dose changed.
  • Tetrabenazine May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects.
  • Thioridazine Increased risk of cardiotoxicity and arrhythmias
  • Thiothixene May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
  • Tolterodine Haloperidol may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
  • Toremifene Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
  • Tramadol Haloperidol may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Haloperidol may decrease the effect of Tramadol by decreasing active metabolite production.
  • Trazodone The CYP3A4 inhibitor, Haloperidol, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Haloperidol by decreasing Haloperidol metabolism and clearance. Monitor for changes in Trazodone and Haloperidol efficacy/toxicity if either agent is initiated, discontinued or dose changed.
  • Tridihexethyl The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Trihexyphenidyl The anticholinergic increases the risk of psychosis and tardive dyskinesia
  • Trimethobenzamide Trimethobenzamide and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
  • Trimipramine Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
  • Triprolidine Triprolidine and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
  • Trospium Trospium and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
  • Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of haloperidol if voriconazole is initiated, discontinued or dose changed.
  • Vorinostat Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
  • Ziprasidone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
  • Zuclopenthixol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Liều Lượng & Cách Dùng : Liquid - Intramuscular
Liquid - Oral
Solution - Oral
Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Janssen-Cilag
    Sản phẩm biệt dược : Aloperidin
  • Công ty : Firma
    Sản phẩm biệt dược : Bioperidolo
  • Công ty : Pfizer
    Sản phẩm biệt dược : Brotopon
  • Công ty : Rosemont
    Sản phẩm biệt dược : Dozic
  • Công ty :
    Sản phẩm biệt dược : Duraperidol
  • Công ty :
    Sản phẩm biệt dược : Einalon S
  • Công ty : Merckle
    Sản phẩm biệt dược : Eukystol
  • Công ty : Janssen-Cilag
    Sản phẩm biệt dược : Haldol
  • Công ty : Shionogi Seiyaku
    Sản phẩm biệt dược : Halosten
  • Công ty : Sumitomo
    Sản phẩm biệt dược : Keselan
  • Sản phẩm biệt dược : Linton
  • Công ty : lsei
    Sản phẩm biệt dược : Peluces
  • Công ty : Pfizer
    Sản phẩm biệt dược : Serenace
  • Công ty : Siegfried
    Sản phẩm biệt dược : Sigaperidol
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00502
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=3559
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508794
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C01814
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00136
ChemSpider
http://www.chemspider.com/Chemical-Structure.3438.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21398
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0121-0581-04
PharmGKB
http://www.pharmgkb.org/drug/PA449841
Wikipedia
http://en.wikipedia.org/wiki/Haloperidol
RxList
http://www.rxlist.com/cgi/generic/haloper.htm
Drugs.com
http://www.drugs.com/cdi/haloperidol.html
... loading
... loading